A Comparison Between the Efficacy of Venlafaxine and Duloxetine in Improving Chemotherapy-Induced Chronic Neurotoxicity in Cancer Patients
Hanzaleh Jour Ebrahimiyan; Nafise Ansarinejad; Farshid Fardad · 2023 · Disease and Diagnosis
WASTE classifies this as Negative / Null Result Report · AI classification, approximate
The study found no significant effect — useful as a negative control or null benchmark for your own design.
Abstract
Background: Chemotherapy-induced peripheral neuropathy is one of the most common side effects of chemotherapy. This study aimed to determine the effectiveness of venlafaxine and duloxetine in improving chronic neurotoxicity induced by chemotherapy in cancer patients. Materials and Methods: The study was performed on cancer patients undergoing outpatient chemotherapy or hospitalization in Rasoul Akram hospital. The admitted patients were blindly divided into two groups. The first group was treated with venlafaxine, and the second group was treated with duloxetine. The treatment lasted up until
Abstract by Hanzaleh Jour Ebrahimiyan; Nafise Ansarinejad; Farshid Fardad, Disease and Diagnosis (2023) — licensed CC BY 4.0.
About to run something similar?
Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.
Related failures
A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke
Negative / Null Result ReportDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
Negative / Null Result ReportStenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis
Negative / Null Result ReportEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Replication FailureA Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Negative / Null Result ReportSpironolactone for Heart Failure with Preserved Ejection Fraction
WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.
Metadata source: DOAJ · DOI 10.34172/ddj.2023.389
